UK markets close in 3 hours 5 minutes

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.5000-0.0200 (-1.32%)
At close: 04:00PM EDT

Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway SE
Suite 1900
Atlanta, GA 30339
United States
678 392 3419

Full-time employees8

Key executives

NameTitlePayExercisedYear born
Dr. Milton H. Werner Ph.D.CEO, President & Director697.96kN/A1964
Mr. Garth Lees-Rolfe CPAChief Financial OfficerN/AN/A1985
Dr. Surendra SinghHead of Chemistry, Manufacturing & ControlsN/AN/AN/A
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardN/AN/AN/A
Dan WilliamsControllerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Corporate governance

Inhibikase Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.